Sarepta Therapeutics, Inc. (SRPT) stock analysis
In our weekly check, Sarepta Therapeutics, Inc. is graded D (A to F). Of 23 checks on debt, profit, cash flow and trend: 6 pass, warnings: 7, red flags: 10.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SRPT.
What our checks show for SRPT
Red flags
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The gross margin fell by 29.9 points, to 56.2%: costs are rising faster than prices.
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Analysts expect revenue to shrink about 15% a year.
- The net margin is only 0.8%: little room if costs rise.
- Free cash flow is negative (-1.6% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 67.4% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 93% from a peak. Would you have held through that?
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Net debt is 3.7x a year of EBITDA (debt/equity 0.69). That limits room in a downturn and raises refinancing risk.
- Analysts expect earnings per share to shrink about 72.1% a year.
- Analysts expect the net margin to shrink by 0.6 points from today's 0.8%.
- Earnings per share fell 77.6% a year over the last 3 years.
- A small company (market value $1.72 billion): usually riskier and followed by fewer analysts.
- The stock is still below its previous peak.
- The share count grew by 13.4% in 2 years: each shareholder owns a smaller slice.
Strengths
- The net margin rose by 60.4 points over 5 years, to 0.8%.
- Revenue grew 28% a year over the last 3 years.
- Beta 0.2: the stock usually moves less than the market.
- Actively traded: about 2.7 million shares a day.
Similar companies
VIR · STOK · NRIX · QURE · RARE · PGEN
Questions
What grade does Sarepta Therapeutics, Inc. (SRPT) have?
In our weekly check, Sarepta Therapeutics, Inc. is graded D (A to F). Of 23 checks on debt, profit, cash flow and trend: 6 pass, warnings: 7, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of SRPT stock?
This week's biggest flags for Sarepta Therapeutics, Inc.: Weak interest cover, Gross margin falling, Profits not backed by cash. In total 17 of 23 checks show a warning or a red flag.
What does Sarepta Therapeutics, Inc. do?
Sarepta Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SRPT.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis